Biocon Limited Q2 FY26 Concall Decoded: Revenue up 20%, biosimilars on fire, debt exits done — and management says the real margin party starts in FY27
1. Opening Hook
While most pharma CEOs are busy explaining “temporary headwinds,” Biocon decided Q2 FY26 was the perfect time to quietly clean up its balance sheet, launch five biosimilars, and tell analysts that ₹300 crore of annual interest savings are coming — just not immediately.
The stock market wanted fireworks. Biocon delivered spreadsheets. Biosimilars are accelerating, insulin is finding new political allies in California, and debt investors are being shown the exit door one by one. Yet reported PAT still looks unimpressive, because apparently timing matters more than optics.
If you came looking for short-term sugar highs, this call will disappoint you. If you enjoy watching leverage unwind while operating leverage kicks in, keep reading. It only gets more interesting once the interest cost stops shouting over the business performance.
2. At a Glance
Revenue up 20% YoY – Growth without price hikes; volumes doing the heavy lifting.
Biosimilars up 25% – Finally behaving like the core engine, not a side bet.
Core EBITDA margin at 28% – Before debt stops stealing the spotlight.
Reported PAT ₹85 cr – Looks weak until you read the footnotes.
